- Home
- DOCU vs EXEL Comparison
DOCU vs EXEL Comparison
Compare DOCU & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCU | EXEL |
|---|---|---|
| Founded | 2003 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 11.1B |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DOCU | EXEL |
|---|---|---|
| Price | $46.77 | $43.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 22 |
| Target Price | ★ $86.57 | $46.24 |
| AVG Volume (30 Days) | ★ 4.4M | 2.6M |
| Earning Date | 03-12-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | 1.44 | ★ 2.38 |
| Revenue | ★ $3,158,892,000.00 | $2,288,218,000.00 |
| Revenue This Year | $10.02 | $9.47 |
| Revenue Next Year | $6.81 | $12.26 |
| P/E Ratio | $32.73 | ★ $18.47 |
| Revenue Growth | 8.45 | ★ 9.93 |
| 52 Week Low | $45.00 | $32.38 |
| 52 Week High | $99.30 | $49.62 |
Technical Indicators
Market Signals| Indicator | DOCU | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 23.08 | 47.59 |
| Support Level | $45.00 | $42.17 |
| Resistance Level | $58.96 | $43.70 |
| Average True Range (ATR) | 2.24 | 1.37 |
| MACD | -0.94 | -0.15 |
| Stochastic Oscillator | 10.03 | 49.50 |
Price Performance
Historical ComparisonAbout DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.